Market Cap 6.88B
Revenue (ttm) 0.00
Net Income (ttm) -260.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 333,400
Avg Vol 465,042
Day's Range N/A - N/A
Shares Out 72.71M
Stochastic %K 74%
Beta 1.31
Analysts Strong Sell
Price Target $125.44

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 357 7000
Address:
One Broadway, 14th Floor, Cambridge, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:44 AM
$NUVL is currently trading at $96.5, which is above its 30-day moving average (MA30) of $92.92 and significantly above the 50-day moving average (MA50) of $88.03, indicating a bullish trend. The RSI at 48.29 suggests a neutral momentum, providing potential for upward movement if buying pressure increases. The recent 60-day high of $104.9 presents a resistance level, while the low of $73.28 indicates a solid support zone. Given this context, a directional bias leans bullish, as the price is above both MAs, and the recent price action shows resilience. Suggested entry: $97.00. Stop loss: $92.00 (below MA30). Targets: $102.00 (near 60D high) and $106.00 (potential breakout target). Monitor for volume increases to confirm the upward momentum. https://privateprofiteers.com
0 · Reply
BioRich
BioRich Nov. 14 at 10:52 PM
$NUVL This will Trend #1 over the weekend. Reasonable shares that are expected to jump Monday pre-market. Exciting news coming! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 9:46 PM
After Hours Top Gainers PT2 $DFLI $NUVL $BNZI $SMLR $MDAI
0 · Reply
Icarus81
Icarus81 Nov. 14 at 9:44 PM
$NUVL CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:17 AM
$NUVL is currently trading at $94.68, sitting above its 30-day moving average (MA30) of $92.51 and significantly above its 50-day moving average (MA50) of $87.72, indicating a bullish trend. The RSI at 51.7 suggests that the stock is neither overbought nor oversold, allowing for potential upward movement. The recent 60-day high of $104.9 provides a key resistance level, while the low of $71.68 indicates a solid support range. Directional bias leans bullish given the price's position relative to the MAs and the RSI's neutral stance. Suggested entry is at $95.00, with a stop loss set at $89.50 to manage risk. Target 1 is $102.00, near the 60-day high, and Target 2 is $105.00 for potential breakout gains. This trade plan leverages current market conditions and technical indicators to capitalize on upward momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:24 AM
$NUVL: The last close at $96.15 indicates a strong position within the recent price range. The RSI at 57.08 suggests bullish momentum, as it is above the neutral 50 level but not yet overbought. The 30-day moving average (MA30) at $91.67 and the 50-day moving average (MA50) at $87.07 indicate a positive trend, with the current price above both MAs, confirming upward momentum. The 60-day high of $104.9 provides a potential resistance level, while the low of $71.68 indicates a solid support base. Directional bias is bullish due to the positive RSI and the price being above key moving averages. Suggested entry: $96.50 (slightly above last close for confirmation). Stop: $91.00 (below MA30 for risk management). Targets: $102.00 (near 60D high) and $105.00 (psychological resistance). This plan capitalizes on current momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 12:06 PM
Canaccord Genuity has updated their rating for Nuvalent ( $NUVL ) to Buy with a price target of 126.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:00 AM
$NUVL: The last close at $96.15 indicates a strong position within the recent price range. The RSI at 57.08 suggests bullish momentum, as it is above the neutral 50 level but not yet overbought. The 30-day moving average (MA30) at $91.67 and the 50-day moving average (MA50) at $87.07 indicate a positive trend, with the current price above both MAs, confirming upward momentum. The 60-day high of $104.9 provides a potential resistance level, while the low of $71.68 indicates a solid support base. Directional bias is bullish due to the positive RSI and the price being above key moving averages. Suggested entry: $96.50 (slightly above last close for confirmation). Stop: $91.00 (below MA30 for risk management). Targets: $102.00 (near 60D high) and $105.00 (psychological resistance). This plan capitalizes on current momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:10 PM
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 5 at 11:19 AM
WATCHLIST NOV 05 2025 $NUVL Nuvalent To Present Patient-Reported Outcomes Data From The Phase 2 Portion Of The ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And Encore Pivotal Efficacy And Safety Data From The ARROS-1 Trial At 2025 IASLC ASCO North America Conference On Lung Cancer $TNYA Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025 $RIGL Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. $CYRX Needham Maintains Buy on CryoPort, Raises Price Target to $12 $NVO Novo Nordisk CEO Says Company Expanding Telehealth For Obesity Care, Confident In Pipeline But Seeking More Candidates; CFO Notes Growth Deceleration Toward Year-End
0 · Reply
Latest News on NUVL
Nuvalent: Interesting Product, But Aggressive Valuation

Nov 4, 2025, 9:28 PM EST - 10 days ago

Nuvalent: Interesting Product, But Aggressive Valuation


Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 24, 2025, 6:30 AM EDT - 7 weeks ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day


Nuvalent Appoints Christy Oliger to Board of Directors

Jun 18, 2025, 4:30 PM EDT - 5 months ago

Nuvalent Appoints Christy Oliger to Board of Directors


Nuvalent to Participate in Upcoming March Investor Conferences

Feb 28, 2025, 6:30 AM EST - 9 months ago

Nuvalent to Participate in Upcoming March Investor Conferences


Nuvalent: A Logical Acquisition Target

Jan 10, 2025, 1:22 PM EST - 11 months ago

Nuvalent: A Logical Acquisition Target


Nuvalent Appoints Grant Bogle to Board of Directors

Dec 9, 2024, 6:30 AM EST - 1 year ago

Nuvalent Appoints Grant Bogle to Board of Directors


Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform


Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data


Nuvalent Announces Public Offering of Common Stock

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Nuvalent Announces Public Offering of Common Stock


Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Nuvalent: Making Precise Progress In Its Oncology Pipeline


Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Jun 17, 2024, 12:19 PM EDT - 1 year ago

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments


Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14, 2024, 7:15 AM EDT - 1 year ago

Nuvalent: NVL-655 Could Bring Blockbuster Potential


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:44 AM
$NUVL is currently trading at $96.5, which is above its 30-day moving average (MA30) of $92.92 and significantly above the 50-day moving average (MA50) of $88.03, indicating a bullish trend. The RSI at 48.29 suggests a neutral momentum, providing potential for upward movement if buying pressure increases. The recent 60-day high of $104.9 presents a resistance level, while the low of $73.28 indicates a solid support zone. Given this context, a directional bias leans bullish, as the price is above both MAs, and the recent price action shows resilience. Suggested entry: $97.00. Stop loss: $92.00 (below MA30). Targets: $102.00 (near 60D high) and $106.00 (potential breakout target). Monitor for volume increases to confirm the upward momentum. https://privateprofiteers.com
0 · Reply
BioRich
BioRich Nov. 14 at 10:52 PM
$NUVL This will Trend #1 over the weekend. Reasonable shares that are expected to jump Monday pre-market. Exciting news coming! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 9:46 PM
After Hours Top Gainers PT2 $DFLI $NUVL $BNZI $SMLR $MDAI
0 · Reply
Icarus81
Icarus81 Nov. 14 at 9:44 PM
$NUVL CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:17 AM
$NUVL is currently trading at $94.68, sitting above its 30-day moving average (MA30) of $92.51 and significantly above its 50-day moving average (MA50) of $87.72, indicating a bullish trend. The RSI at 51.7 suggests that the stock is neither overbought nor oversold, allowing for potential upward movement. The recent 60-day high of $104.9 provides a key resistance level, while the low of $71.68 indicates a solid support range. Directional bias leans bullish given the price's position relative to the MAs and the RSI's neutral stance. Suggested entry is at $95.00, with a stop loss set at $89.50 to manage risk. Target 1 is $102.00, near the 60-day high, and Target 2 is $105.00 for potential breakout gains. This trade plan leverages current market conditions and technical indicators to capitalize on upward momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:24 AM
$NUVL: The last close at $96.15 indicates a strong position within the recent price range. The RSI at 57.08 suggests bullish momentum, as it is above the neutral 50 level but not yet overbought. The 30-day moving average (MA30) at $91.67 and the 50-day moving average (MA50) at $87.07 indicate a positive trend, with the current price above both MAs, confirming upward momentum. The 60-day high of $104.9 provides a potential resistance level, while the low of $71.68 indicates a solid support base. Directional bias is bullish due to the positive RSI and the price being above key moving averages. Suggested entry: $96.50 (slightly above last close for confirmation). Stop: $91.00 (below MA30 for risk management). Targets: $102.00 (near 60D high) and $105.00 (psychological resistance). This plan capitalizes on current momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 12:06 PM
Canaccord Genuity has updated their rating for Nuvalent ( $NUVL ) to Buy with a price target of 126.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:00 AM
$NUVL: The last close at $96.15 indicates a strong position within the recent price range. The RSI at 57.08 suggests bullish momentum, as it is above the neutral 50 level but not yet overbought. The 30-day moving average (MA30) at $91.67 and the 50-day moving average (MA50) at $87.07 indicate a positive trend, with the current price above both MAs, confirming upward momentum. The 60-day high of $104.9 provides a potential resistance level, while the low of $71.68 indicates a solid support base. Directional bias is bullish due to the positive RSI and the price being above key moving averages. Suggested entry: $96.50 (slightly above last close for confirmation). Stop: $91.00 (below MA30 for risk management). Targets: $102.00 (near 60D high) and $105.00 (psychological resistance). This plan capitalizes on current momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:10 PM
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 5 at 11:19 AM
WATCHLIST NOV 05 2025 $NUVL Nuvalent To Present Patient-Reported Outcomes Data From The Phase 2 Portion Of The ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And Encore Pivotal Efficacy And Safety Data From The ARROS-1 Trial At 2025 IASLC ASCO North America Conference On Lung Cancer $TNYA Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025 $RIGL Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. $CYRX Needham Maintains Buy on CryoPort, Raises Price Target to $12 $NVO Novo Nordisk CEO Says Company Expanding Telehealth For Obesity Care, Confident In Pipeline But Seeking More Candidates; CFO Notes Growth Deceleration Toward Year-End
0 · Reply
IN0V8
IN0V8 Nov. 4 at 7:21 PM
$NUVL Added at $91.04
0 · Reply
IN0V8
IN0V8 Oct. 31 at 7:41 PM
$NUVL Opportunity Barclays raises target price to $112 from $100 UBS raises target price to $132 from $114
0 · Reply
jb06000
jb06000 Oct. 31 at 10:51 AM
$NUVB Nuvation Bio is currently deeply undervalued at around $ 1.8 billion, especially when compared to its key peer, Nuvalent ($NUVL), which is valued near aroud $ 7 billion for a similar oncology pipeline. NUVB’s lead asset, Taletrectinib. Is the current best-in-class blockbuster for ROS1+ cancer, this could drive peak sales of $ 2.5B–$ 4.0B. The progress of a second pivotal asset, Safusidenib, significantly de-risks. Furthermore, a strong balance sheet with non-dilutive financing ensures robust execution. NUVB warrants a premium or at least parity with NUVL, making the $ 8 billion valuation a justified, conservative NPV of its near-commercial future; this would be $ 20 a share.
0 · Reply
d_risk
d_risk Oct. 31 at 8:04 AM
$NUVL - Nuvalent Inc. Class A Common Stock - 10Q - Updated Risk Factors NUVL’s updated 10-Q risk factors spotlight deepening losses, no revenue, and heavy reliance on successful clinical trials and regulatory approvals. Expanded disclosures detail commercialization inexperience, manufacturing and supply risks, market acceptance hurdles, evolving global regulations, patent uncertainties, and heightened competition, while removing some prior specifics and adding new risks on data security, insurance gaps, and international marketing. #Biotechnology #DataSecurity #MarketAcceptance #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NUVL/10-Q/2025-10-30
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 30 at 3:06 PM
$NUVB $NUVL Lol! Nuvalent lost 27 million more than the 95 million they were expected to lose this quarter, for a total loss of 122 million. I'll stick with Nuvation Bio.
0 · Reply
Doozio
Doozio Oct. 28 at 7:28 PM
$NUVB $NUVL 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Oct. 27 at 12:50 PM
Piper Sandler⬆️ $NUVL's PT to $128 from $112, reiterated at Overweight, and said, Could 1L ALK Be $8B+? Upcoming ALKOVE-1 Update Underappreciated $BMY $PFE $RHHBY $NUVB Piper Sandler added: NUVL will present pivotal Ph. II ALKOVE-1 data of key value driver, neladalkib, in 2L+ ALK+ NSCLC any day (guided for 4Q). We think the Street, with eyes on the 1L ALK opportunity, is underestimating the potential impact of this dataset. While investors we have spoken to recently think the TKI pre-treated data is already priced in at these levels, we think the 2L data specifically (and its implications on 1L & 2L TAM) could move NUVL shares +18%- to +24%. Raising our PT to $128.
1 · Reply
jb06000
jb06000 Oct. 21 at 3:56 PM
$NUVL take your profit jump to NUVB this will crash one approved.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 18 at 2:29 PM
$NUVL 4 insiders just dumped another 11 million dollars worth of stock this week. Seems insiders have no confidence in the future of this company. Just look at that sea of red. https://www.secform4.com/insider-trading/1861560.htm
0 · Reply
vu_jade
vu_jade Oct. 17 at 2:55 AM
$NUVL ready to rock
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 2:29 PM
$SNDX , $BDTX , $RVMD , $VSTM , $NUVL ... H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments. https://notreload.xyz/sndx-bdtx-rvmd-vstm-nuvl-buy-ratings/
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 16 at 1:56 PM
$NUVB This is completely f*****n nuts for this to be trading down right now as the XBI is trading up over 2.00 again and $NUVL is up another 2.70 on 90,000 volume, as the insiders there continue to dump their shares.
1 · Reply